'%3e%3cpath%20d='M34.1406%205.85938C30.3906%202.10547%2025.3047%200%2020%200C14.6953%200%209.60938%202.10547%205.85938%205.85938C2.10938%209.61328%200%2014.6953%200%2020C0%2025.3047%202.10547%2030.3906%205.85938%2034.1406C9.61328%2037.8906%2014.6953%2040%2020%2040C25.3047%2040%2030.3906%2037.8945%2034.1406%2034.1406C37.8906%2030.3906%2040%2025.3047%2040%2020C40%2014.6953%2037.8945%209.60938%2034.1406%205.85938ZM37.0117%2023.543H31.1602V13.5391H27.6328V19.9414C28.1211%2020.6914%2028.3711%2021.582%2028.3711%2022.5625V22.625C28.3711%2023.668%2028.1172%2024.6055%2027.6328%2025.4297V26.6094H36.082C33.4883%2032.9375%2027.2891%2037.3789%2020.0039%2037.3789C10.3711%2037.3789%202.62109%2029.6289%202.62109%2020C2.62109%2010.3711%2010.3711%202.62109%2020%202.62109C29.6289%202.62109%2037.3789%2010.3711%2037.3789%2020C37.3789%2021.1484%2037.2617%2022.2656%2037.0508%2023.3477C37.0391%2023.4141%2037.0234%2023.4766%2037.0117%2023.543Z'%20fill='white'/%3e%3cpath%20d='M22.3086%2018.5352C20.4336%2018.125%2019.9531%2017.8398%2019.9766%2017.1836V17.1406C19.9766%2016.6992%2020.3477%2016.2148%2021.4023%2016.2148C22.582%2016.2148%2023.8867%2016.6797%2025.0781%2017.4766L26.8516%2015.0195C25.4453%2013.8906%2023.707%2013.3398%2021.5547%2013.3398C18.5195%2013.3398%2016.4375%2015%2016.4063%2017.4766V17.5352C16.3633%2020.2617%2018.5859%2020.9805%2021.293%2021.6016C23.0391%2021.9766%2023.5703%2022.3164%2023.5703%2022.9609L23.5469%2022.9766C23.5469%2023.3906%2023.2578%2023.7031%2022.7852%2023.8359C22.5742%2023.9062%2022.1289%2023.9727%2021.5156%2023.9727C20.7617%2023.9727%2019.7539%2023.8633%2018.6328%2023.4844C18.0898%2023.2891%2017.4727%2023.0039%2016.8047%2022.6133L20.1406%2026.625C20.2813%2026.6602%2021.0977%2026.8516%2021.7734%2026.8516C25.0039%2026.8516%2027.0859%2025.2461%2027.1094%2022.6328V22.5703C27.1602%2020.1133%2025.2148%2019.1719%2022.3086%2018.5352Z'%20fill='white'/%3e%3cpath%20d='M5.24219%2013.5664V26.6133H8.75391V23.7578L10.2969%2021.9531L14.2031%2026.6133H18.3867L12.3555%2019.5195L17.4023%2013.5664H13.4531L8.75391%2019.0586V13.5664H5.24219Z'%20fill='white'/%3e%3c/g%3e%3cdefs%3e%3cclipPath%20id='clip0_97_2430'%3e%3crect%20width='40'%20height='40'%20fill='white'/%3e%3c/clipPath%3e%3c/defs%3e%3c/svg%3e)
Lifestyle Features
Most Recent
Weight Watchers names Stephen Bye as CEO
Reuters | Updated Sept. 9 - 8:48 a.m. | Save Story
WW International on Wednesday named Stephen Bye as its chief executive officer, effective this fall.
Roivant's experimental lung disease drug meets goals in mid-stage study
Sahil Pandey, Reuters | Updated Sept. 9 - 3:23 a.m. | Save Story
Roivant said on Tuesday its experimental drug met the main goals of a mid-stage study in patients with high blood pressure associated with a type of lung disease, sending shares up about 17%.
Amgen-AstraZeneca lung cancer drug combo boosts survival in late-stage trial
Reuters | Updated Sept. 8 - 2:26 p.m. | Save Story
Amgen's targeted immunotherapy, Imdelltra, combined with AstraZeneca's cancer drug Imfinzi, significantly improved overall survival in patients with extensive-stage small-cell lung cancer in a late-stage trial, the companies said on Tuesday.
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
Sriparna Roy, Reuters | Updated Sept. 8 - 1:24 p.m. | Save Story
Shares of Dyne Therapeutics and Sarepta slumped on Tuesday after Novartis' treatment for a muscle-wasting disorder failed in a trial, fueling investor concerns about the prospects of similar therapies for the tough-to-treat rare disease.
Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study
Sneha S K, Reuters | Updated Sept. 8 - 12:03 p.m. | Save Story
Inhibrx Biosciences said on Tuesday its experimental combination cancer drug helped reduce tumors in a mid-stage study in patients with a type of head and neck cancer.
Is summer heat hurting your trees? The fix may be less water, not more
David Een, KSL | Posted Sept. 8 - 12:02 p.m. | Save Story
Utah's intense summer heat can leave trees looking scorched, tired, or unhealthy, but the solution is not always more water. Learn how proper deep, infrequent watering, soil care, and mulch can help trees better handle late-summer stress.
Sandoz bets big on biosimilars, aims to double group sales by 2035
Bhanvi Satija and Marleen Kaesebier, Reuters | Updated Sept. 8 - 11:18 a.m. | Save Story
Swiss drugmaker Sandoz aims to more than double its annual net sales by 2035, with a majority coming from biosimilar medicines, the company said at its capital markets day on Tuesday.
Novartis twin drug trial setbacks pile pressure on pipeline, CEO
Bhanvi Satija, Dave Graham and Marleen Kaesebier, Reuters | Updated Sept. 8 - 11:14 a.m. | Save Story
Novartis said on Tuesday its experimental drug for a muscle-wasting disorder failed a late-stage study, the second major trial setback in days, sending the Swiss drugmaker's shares down about 11% in its worst trading day on record.
AI healthcare platform Forus valued at $3 billion in latest funding round
Reuters | Updated Sept. 8 - 9:33 a.m. | Save Story
AI healthcare platform Forus said on Tuesday it has raised $150 million in a funding round that valued the company at $3 billion, tripling its valuation in about four months.
Grasshopper populations low in Utah, but homeowners should stay prepared
David Een, KSL | Updated Sept. 8 - 9:26 a.m. | Save Story
Grasshopper populations were expected to be high in Utah after a mild winter, but numbers have been surprisingly low across much of the state. Learn why grasshopper outbreaks are difficult to predict and what homeowners can do now to prepare for future infestations.
Pharvaris' genetic disorder drug meets main goal in late-stage trial
Kunal Das, Reuters | Updated Sept. 8 - 8:36 a.m. | Save Story
Pharvaris said on Tuesday its experimental oral drug helped prevent swelling attacks in patients with hereditary angioedema, meeting the main goal of a late-stage trial.
Bristol Myers' blood cancer cell therapy succeeds in mid-stage trial
Reuters | Updated Sept. 8 - 7:10 a.m. | Save Story
Bristol Myers Squibb said on Tuesday its experimental cell therapy showed a high overall response rate in a mid-stage trial, in patients with a hard-to-treat form of blood cancer.
Utahns flock to Millcreek Canyon for affordable Labor Day getaway
VideoAnnette Campbell, KSL | Updated Sept. 8 - 6:39 a.m. | Save Story
Cooler temperatures on Monday drew hikers, bikers and families to Millcreek Canyon for one last summer outing before fall approaches.
Waves of layoffs are sweeping across Utah. Here's what workers losing their jobs should know
Art Raymond, Deseret News | Posted Sept. 7 - 9:01 p.m. | Save Story
While job cuts are down, the growth rate of the U.S. employment sector has also slowed — and Utahns are not immune. Here's what to know if you're one of those without a job.
25 years later, 9/11 responders are still dying from illnesses tied to the attacks
John Domen, WTOP | Updated Sept. 7 - 8:28 p.m. | Save Story
The Sept. 11, 2001 attacks killed thousands of people in a matter of hours. Nearly 25 years later, illnesses tied to response efforts continue claiming lives. More than 400 FBI employees have been diagnosed, and dozens have died.
Novartis cholesterol setback tests hopes for emerging heart disease drugs
Bhanvi Satija, Reuters | Updated Sept. 7 - 5:25 a.m. | Save Story
Shares of Novartis fell more than 3% on Monday after its cholesterol drug failed in a closely watched study, dealing a blow to what investors had seen as a blockbuster treatment and raising pressure on upcoming data from a muscle-wasting therapy acquired through the Swiss drugmaker's $12 billion purchase of Avidity.
Novo Nordisk says semaglutide cut obesity rates in young children in trial
Reuters | Updated Sept. 7 - 5:03 a.m. | Save Story
Novo Nordisk said on Monday that in a late-stage trial, 40.4% of children aged 6 to under 12 treated with semaglutide, the active ingredient in its blockbuster weight-loss drug Wegovy, were no longer classified as having obesity after 68 weeks, assuming full adherence to the treatment.
Bubs Australia gets permanent FDA nod for infant formula sales in US, shares jump
Reuters | Updated Sept. 7 - 1:20 a.m. | Save Story
Bubs Australia said on Monday it secured permanent authorisation from the U.S. Food and Drug Administration to sell three infant formula products in the country, sending its shares up 30% to their highest close since mid-February.
